CA2300694A1 - Derives d'acide furansulfonique et compositions pharmaceutiques les contenant - Google Patents

Derives d'acide furansulfonique et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
CA2300694A1
CA2300694A1 CA002300694A CA2300694A CA2300694A1 CA 2300694 A1 CA2300694 A1 CA 2300694A1 CA 002300694 A CA002300694 A CA 002300694A CA 2300694 A CA2300694 A CA 2300694A CA 2300694 A1 CA2300694 A1 CA 2300694A1
Authority
CA
Canada
Prior art keywords
group
hydrogen
cycloalkyl
independently selected
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300694A
Other languages
English (en)
Inventor
Judith A. Kelleher
Kirk R. Maples
Yong-Kang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaur Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300694A1 publication Critical patent/CA2300694A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention concerne des dérivés d'acide furansulfonique et des compositions pharmaceutiques les contenant. Lesdites compositions sont utiles pour la prévention et/ou le traitement d'états neurodégénératifs, autoimmuns et inflammatoires chez les mammifères.
CA002300694A 1997-08-18 1998-08-18 Derives d'acide furansulfonique et compositions pharmaceutiques les contenant Abandoned CA2300694A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5591697P 1997-08-18 1997-08-18
US60/055,916 1997-08-18
PCT/US1998/016458 WO1999009022A1 (fr) 1997-08-18 1998-08-18 Derives d'acide furansulfonique et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CA2300694A1 true CA2300694A1 (fr) 1999-02-25

Family

ID=22001003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300694A Abandoned CA2300694A1 (fr) 1997-08-18 1998-08-18 Derives d'acide furansulfonique et compositions pharmaceutiques les contenant

Country Status (8)

Country Link
US (1) US5994396A (fr)
EP (1) EP1005463A1 (fr)
JP (1) JP2001515074A (fr)
CN (1) CN1271353A (fr)
AU (1) AU8899698A (fr)
CA (1) CA2300694A1 (fr)
NZ (1) NZ502741A (fr)
WO (1) WO1999009022A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098873B1 (fr) 1998-07-17 2004-05-26 Renovis, Inc. Composes de alpha-2(2-hydroxyphenyl)nitrone, compositions pharmaceutiques les renfermant et leur utilisation dans le traitement des inflammations
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
WO2008121850A2 (fr) * 2007-03-30 2008-10-09 University Of Rochester Modulateurs de type petite molécule, de l'expression de la mélanine
SG10201608528YA (en) 2011-12-21 2016-12-29 Novira Therapeutics Inc Hepatitis b antiviral agents
CR20200276A (es) 2012-08-28 2021-01-27 Janssen Sciences Ireland Uc Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
CA2922302C (fr) 2013-04-03 2021-08-03 Janssen Sciences Ireland Uc Derives de n-phenylcarboxamide et leur utilisation comme medicaments pour le traitement de l'hepatite b
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CA2935719C (fr) 2013-07-25 2021-11-02 Janssen Sciences Ireland Uc Derives de pyrrolamide a substitution glyoxamide et leur utilisation en tant que medicaments pour le traitement de l'hepatite b
AP2016009122A0 (en) 2013-10-23 2016-03-31 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
WO2016149581A1 (fr) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2016330964B2 (en) 2015-09-29 2021-04-01 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
EA202092171A1 (ru) 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида
CN108658907B (zh) * 2018-06-07 2021-08-13 广东药科大学 一类具有消炎免疫活性的磺酰基取代呋喃类化合物及其衍生物
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
CN113795486A (zh) 2019-05-06 2021-12-14 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844573A (en) * 1955-12-23 1958-07-22 Monsanto Chemicals Catalytic hydrogenation
US4195023A (en) * 1975-08-20 1980-03-25 Merck & Co., Inc. 2-(2-Furoyl)1,2-benzisothiazole-3-one, 2-(2-furoyl) saccharin, and 2-(2-thenoyl) saccharin
GB8302499D0 (en) * 1983-01-29 1983-03-02 Wyeth John & Brother Ltd Benzoquinolizines
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
EP0735821A4 (fr) * 1993-12-21 1998-04-01 Lilly Co Eli Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amylo dogenes
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
NZ502741A (en) 2003-02-28
US5994396A (en) 1999-11-30
WO1999009022A1 (fr) 1999-02-25
AU8899698A (en) 1999-03-08
CN1271353A (zh) 2000-10-25
EP1005463A1 (fr) 2000-06-07
JP2001515074A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
CA2300694A1 (fr) Derives d'acide furansulfonique et compositions pharmaceutiques les contenant
CA3078391C (fr) Inhibiteurs d'endonuclease dependant du cap
US6046232A (en) α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
AU2006224853B2 (en) Trifluoromethylbenzamide derivatives and therapeutic uses thereof
EP0877018A1 (fr) Acides sulfonylaminocarboxyliques
EP0525111B1 (fr) Acides hydroxamiques et n-hydroxy-urees anti-inflammatoires
WO2022084741A1 (fr) Composés modulateurs de cftr, compositions et utilisations associées
US5942507A (en) Furan nitrone compounds
US5998469A (en) Thioether furan nitrone compounds
US3769292A (en) N-(pyridyl)2h 1-benzothiopyran-3-carboxamide-4-hydroxy 1,1-dioxides
EP1047688B1 (fr) Composes thiophene-nitrone
US4293713A (en) Novel 1,1,3,5-substituted biuret compound and a pharmaceutical composition containing the same
JP2023552516A (ja) Ｏ－ＧｌｃＮＡｃａｓｅ阻害活性を有する化合物およびその用途
US3297699A (en) 5-nitrothiazolyl-dioxo-diazacycloalkanes
KR101621444B1 (ko) 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물
WO1997034881A1 (fr) Derives bis-heterocycliques
US6011174A (en) Cyclic amic acid derivatives
US5981573A (en) N,N-disubstituted amic acid derivatives
EP0588850B1 (fr) Derives de n-hydroxy-uree inhibant la lipoxygenase
US3356684A (en) Novel compositions for the treatment of helminthiasis
WO2023067388A1 (fr) Utilisations de composés modulateurs de cftr et/ou inhibiteurs de pde4
LV14476B (lv) Bioloģiski aktīvu 4-acilamino-4,5,6,7-tetrahidroindazolu sintēze
AU2003227320A1 (en) Thiophene nitrone compounds
JPH01319477A (ja) 新規１，２−ジチオール−３−チオン誘導体およびそれを有効成分とする免疫調節剤
JPH02233609A (ja) オキサミド酸化合物及び脳機能障害改善薬

Legal Events

Date Code Title Description
FZDE Discontinued